e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Prognostic laboratory tests in community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia
E. M. W. van de Garde, H. Endeman, V. H. M. Deneer, D. H. Biesma, F. A. Sayed-Tabatabaei, H. J. T. Ruven, H. G. M. Leufkens, J. M. M. van den Bosch (Nieuwegein, Utrecht, The Hague, Netherlands)
Source:
Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Session:
Prognostic laboratory tests in community-acquired pneumonia
Session type:
Oral Presentation
Number:
2920
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. M. W. van de Garde, H. Endeman, V. H. M. Deneer, D. H. Biesma, F. A. Sayed-Tabatabaei, H. J. T. Ruven, H. G. M. Leufkens, J. M. M. van den Bosch (Nieuwegein, Utrecht, The Hague, Netherlands). Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia. Eur Respir J 2007; 30: Suppl. 51, 2920
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS
Source: Eur Respir J 2007; 29: 482-488
Year: 2007
Defining stability in pneumonia and the non-responding pneumonia
Source: Annual Congress 2005 - Outcome in severe pneumonia
Year: 2005
Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population
Source: Eur Respir J 2006; 27: 1217-1222
Year: 2006
The influence of genetics on mortality from pneumonia
Source: Annual Congress 2005 - Outcome in severe pneumonia
Year: 2005
Management-based risk prediction in community-acquired pneumonia by scores and biomarkers
Source: Eur Respir J 2013; 41: 974-984
Year: 2013
Genetic susceptibility to severe community-acquired pneumonia (CAP) in Buenos Aires
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia
Source: Eur Respir J 2008; 31: 611-617
Year: 2008
Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
Factors associated with unknown aetiology in patients with community-acquired pneumonia
Source: Eur Respir J 2002; 20: 1254-1262
Year: 2002
Microbial evaluation of proton-pump inhibitors and the risk of pneumonia
Source: Eur Respir J 2011; 38: 1165-1172
Year: 2011
Influence of chronic cardiovascular diseases (CVD) on course and outcome of community-acquired pneumonia (CAP)
Source: International Congress 2017 – The acute patient: the clinical point-of-view
Year: 2017
The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008
COPD is associated with increased mortality in patients with community-acquired pneumonia
Source: Eur Respir J 2006; 28: 346-351
Year: 2006
Validation of a computer predictive model to stratify risk and site of care in community acquired pneumonia (CAP)
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005
The association of angiotensin-converting enzyme gene insertion/deletion polymorphisms with OSA: a meta-analysis
Source: Eur Respir J 2012; 40: 394-399
Year: 2012
Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor
Source: Eur Respir J 2004; 24 : 779-785
Year: 2004
The predictive role of TLR4 +3725 G/C polymorphism in community-acquired pneumonia (CAP) severity course among young respondents with cytomegaloviral persistence (CMVP)
Source: International Congress 2018 – Genetics in chronic pulmonary diseases
Year: 2018
The role of ACE insertion/deletion polymorphism in RDS development in neonates from Russia
Source: Eur Respir J 2005; 26: Suppl. 49, 393s
Year: 2005
Angiotensin-converting enzyme insertion/deletion gene polymorphism and interstitial pulmonary fibrosis in Iranian population
Source: Eur Respir J 2005; 26: Suppl. 49, 542s
Year: 2005
Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)?
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept